Table 4.
Incidence of cardiometabolic comorbidities among Chinese boys with obesity assessed between 2008 and 2017 in Hangzhou (Zhejiang Province, China).
| Boys | Aged <10 years | Aged ≥10 years | ||||
|---|---|---|---|---|---|---|
| 2008–2012 | 2013–2017 | p-Value | 2008–2012 | 2013–2017 | p-Value | |
| N | 298 | 325 | 600 | 731 | ||
| Impaired fasting glucose | 59 (20.1%) | 95 (29.2%) | 0.009 | 132 (22.1%) | 195 (26.7%) | 0.055 |
| Impaired glucose tolerance | 38 (12.9%) | 44 (13.5%) | 0.91 | 76 (12.8%) | 124 (17.0%) | 0.037 |
| Abnormal glycaemia | 78 (26.5%) | 127 (39.1%) | 0.001 | 174 (29.1%) | 276 (37.8%) | 0.001 |
| Type 2 diabetes | 1 (0.3%) | 4 (1.2%) | 0.38 | 9 (1.5%) | 36 (4.9%) | 0.001 |
| Hypertension | 84 (28.4%) | 156 (48.0%) | <0.0001 | 158 (26.5%) | 262 (35.8%) | <0.0001 |
| Dyslipidaemia | 105 (35.4%) | 79 (24.5%) | 0.004 | 253 (42.4%) | 247 (34.2%) | 0.002 |
| Hyperuricaemia | 14 (4.7%) | 18 (5.6%) | 0.72 | 125 (21.2%) | 156 (21.5%) | 0.95 |
| Acanthosis nigricans | 176 (61.5%) | 236 (72.8%) | 0.003 | 414 (69.3%) | 518 (70.9%) | 0.59 |
| Abnormal liver function | 191 (65.0%) | 167 (52.2%) | 0.001 | 393 (68.0%) | 573 (78.6%) | <0.0001 |
| NAFLD | 155 (52.2%) | 158 (48.6%) | 0.38 | 434 (73.4%) | 500 (68.8%) | 0.07 |
| Metabolic syndrome | – | – | – | 222 (37.0%) | 293 (40.1%) | 0.26 |
Data are n (%). p-Values are derived from Fisher’s exact tests, and correspond to comparisons in the incidence of a particular comorbidity between time periods within a given age group. Statistically significant p-values (<0.05) are shown in bold.
NAFLD, non-alcoholic fatty liver disease.